- Home
- JVA vs PYPD Comparison
JVA vs PYPD Comparison
Compare JVA & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVA
- PYPD
- Stock Information
- Founded
- JVA 1971
- PYPD 2008
- Country
- JVA United States
- PYPD Israel
- Employees
- JVA N/A
- PYPD N/A
- Industry
- JVA Packaged Foods
- PYPD Medical/Dental Instruments
- Sector
- JVA Consumer Staples
- PYPD Health Care
- Exchange
- JVA Nasdaq
- PYPD Nasdaq
- Market Cap
- JVA 14.7M
- PYPD 16.3M
- IPO Year
- JVA 2005
- PYPD 2020
- Fundamental
- Price
- JVA $3.48
- PYPD $3.43
- Analyst Decision
- JVA
- PYPD Buy
- Analyst Count
- JVA 0
- PYPD 2
- Target Price
- JVA N/A
- PYPD $12.00
- AVG Volume (30 Days)
- JVA 84.5K
- PYPD 5.2K
- Earning Date
- JVA 10-25-2024
- PYPD 11-06-2024
- Dividend Yield
- JVA N/A
- PYPD N/A
- EPS Growth
- JVA N/A
- PYPD N/A
- EPS
- JVA 0.20
- PYPD N/A
- Revenue
- JVA $76,111,698.00
- PYPD N/A
- Revenue This Year
- JVA N/A
- PYPD N/A
- Revenue Next Year
- JVA N/A
- PYPD N/A
- P/E Ratio
- JVA $17.06
- PYPD N/A
- Revenue Growth
- JVA 17.27
- PYPD N/A
- 52 Week Low
- JVA $0.67
- PYPD $2.95
- 52 Week High
- JVA $3.88
- PYPD $9.20
- Technical
- Relative Strength Index (RSI)
- JVA 60.97
- PYPD 45.44
- Support Level
- JVA $3.07
- PYPD $3.33
- Resistance Level
- JVA $3.77
- PYPD $3.59
- Average True Range (ATR)
- JVA 0.28
- PYPD 0.18
- MACD
- JVA 0.01
- PYPD -0.01
- Stochastic Oscillator
- JVA 73.15
- PYPD 27.27
About JVA Coffee Holding Co. Inc.
Coffee Holding Co Inc is engaged in the business of wholesale coffee operations, including manufacturing, roasting, packaging, marketing and distributing roasted and blended coffees for private labeled accounts and its own brands, and it sells green coffee. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada and certain countries in Asia.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.